Senior Editor Markus Elsner talks to Alex Marson of UCSF about the significance of a
Science paper describing the phase 1 clinical trial of CRISPR-engineered T cells. The work was carried out by Carl June and Edward Stadtmauer from UPenn. Read the paper
here.
Hosted on Acast. See acast.com/privacy for more information.
